Distinguished in Alpha Thalassemia X-Linked Intellectual Disability Syndrome

Overview

Leo Mascarenhas is a Pediatric Hematologist Oncology specialist and a Pediatrics provider in West Hollywood, California. Dr. Mascarenhas and is rated as a Distinguished provider by MediFind in the treatment of Alpha Thalassemia X-Linked Intellectual Disability Syndrome. His top areas of expertise are Hepatoblastoma, Rhabdomyosarcoma, Adult Soft Tissue Sarcoma, Bone Marrow Aspiration, and Tissue Biopsy.

His clinical research consists of co-authoring 96 peer reviewed articles and participating in 88 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Alpha Thalassemia X-Linked Intellectual Disability Syndrome.

Specialties
Pediatric Hematology Oncology
Pediatrics
Hematology
Licenses
Pediatric Hematology-Oncology in CA
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Optima Health

Locations

CEDARS-SINAI MEDICAL CENTER
8700 Beverly Blvd, West Hollywood, CA 90048
310-423-3277

Additional Areas of Focus

Dr. Mascarenhas has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


87 Clinical Trials

A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab With or Without Eflornithine (DFMO) in Children With Relapsed, Refractory or Progressive Neuroblastoma
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid
View 44 Less Clinical Trials
Similar Doctors
Expertise in
26
conditions
Hematology | Oncology
Expertise in
26
conditions
Hematology | Oncology

USC Care Medical Group Inc

1520 San Pablo St, Fl 4, 
Los Angeles, CA 
 (10.3 mi)
Experience:
16+ years
Languages Spoken:
English
Offers Telehealth

Caroline Piatek is a Hematologist and an Oncologist in Los Angeles, California. Dr. Piatek has been practicing medicine for over 16 years and is rated as an Elite provider by MediFind in the treatment of Alpha Thalassemia X-Linked Intellectual Disability Syndrome. Her top areas of expertise are Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Cold Hemoglobinuria, Hemolysis, Splenectomy, and Bone Marrow Aspiration.

Expertise in
40
conditions
Expertise in
40
conditions

USC Care Medical Group Inc

1441 Eastlake Ave, 
Los Angeles, CA 
 (10.2 mi)
Languages Spoken:
English

Ilene Weitz is a Hematologist in Los Angeles, California. Dr. Weitz and is rated as an Elite provider by MediFind in the treatment of Alpha Thalassemia X-Linked Intellectual Disability Syndrome. Her top areas of expertise are Paroxysmal Nocturnal Hemoglobinuria (PNH), Autoimmune Hemolytic Anemia, Hemolytic Anemia, Splenectomy, and Bone Marrow Aspiration.

Expertise in
13
conditions
Pediatric Hematology Oncology | Hematology | Oncology
Expertise in
13
conditions
Pediatric Hematology Oncology | Hematology | Oncology

Childrens Hospital Los Angeles Medical Group Inc

4650 W Sunset Blvd, Ms 87, 
Los Angeles, CA 
 (5.4 mi)
Languages Spoken:
English

Thomas Coates is a Pediatric Hematologist Oncology specialist and a Hematologist in Los Angeles, California. Dr. Coates and is rated as an Elite provider by MediFind in the treatment of Alpha Thalassemia X-Linked Intellectual Disability Syndrome. His top areas of expertise are Hemoglobinopathy, Anemia, Congenital Hemolytic Anemia, Splenectomy, and Bone Marrow Transplant.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile